Trepipam

Trepipam (Trimopam; SCH-12679) is a D1-dopamine receptor antagonist. Trepipam can reduce the self-injurious behavior in 6-OHDA-lesioned rats. Trepipam can be used in the research of epilepsy and anxiety neurosis[1][2][3].

Product Specifications

CAS Number

[20012-08-2]

Product Name Alternative

Trimopam; SCH-12679

UNSPSC

12352005

Target

Dopamine Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease

Smiles

CN1CC(C2=CC(OC)=C(C=C2CC1)OC)C3=CC=CC=C3

Molecular Formula

C19H23NO2

Molecular Weight

297.39

References & Citations

[1]Breese GR, et al. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors. J Pharmacol Exp Ther. 1990 Feb;252 (2) :558-67.|[2]LaPierre Y D. Effectiveness of SCH 12679, a benzazepine, in the treatment of anxiety neurosis[J]. Current Therapeutic Research, 1978.|[3]Lapierre YD, et al. Pharmacologic management of aggressivity and self-mutilation in the mentally retarded. Psychiatr Clin North Am. 1986 Dec;9 (4) :745-54.